Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $77.88 USD
Change Today +0.41 / 0.53%
Volume 5.0M
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

20 On Hatch

Lower Hatch Street

Dublin, 2

Ireland

Phone: 353 1 438 1700

Fax:

rgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures. Neurovascular: The Neurovascular division develops, manufactures, and markets products and therapies to treat diseases of the vasculature in and around the brain. The company’s products include coils, neurovascular stents, and flow diversion products, as well as access and delivery products to support procedures. The following are the principal products offered by its Neurovascular division: The Pipeline and Pipeline Flex Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms; the Solitaire FR revascularization device for treatment of acute ischemic stroke; and the Apollo Onyx delivery micro catheter, the first detachable tip micro-catheter available in the U.S. Customers: The primary medical specialists who use the products of this group include spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, interventional radiologists, and ear, nose, and throat specialists. Competition: The company’s primary competitors include Johnson & Johnson; Boston Scientific; St. Jude; Stryker Corporation (Stryker); NuVasive, Inc.; and Zimmer Holdings, Inc. (Zimmer). Diabetes Group The Diabetes group consists of three divisions (Intensive Insulin Management, Non-Intensive Diabetes Therapies, and Diabetes Services and Solutions) that develop, manufacture, and market advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring (CGM) systems, and therapy management software. The following are the principal products offered by its Diabetes divisions: Integrated Diabetes Management Solutions: The company has the integrated insulin pump and CGM system available on the market. In the U.S., the company offers the MiniMed 530G System featuring its threshold suspend technology, which automatically suspends insulin delivery when glucose levels reach a pre-determined threshold; and newest CGM sensor, Enlite, a sensor that can be worn for 6-days. Outside the U.S., the company offers its MiniMed 640G System, an integrated system with the Enhanced Enlite CGM sensor that features SmartGuard technology, which automatically suspends insulin delivery when sensor glucose levels are predicted to approach a low limit and then resumes insulin delivery once levels recover. Professional CGM: In addition to its Personal CGM (Enlite), the company offers physicians a Professional CGM product called the iPro2/iPro Professional CGM System. Patients wear the iPro2/iPro recorder to capture glucose data that is later uploaded in a physician’s office to reveal glucose patterns and potential problems, including hyperglycemic and hypoglycemic episodes. The data leads to more informed treatment decisions. CareLink Therapy Management Software: The company’s Web-based therapy management software solutions, including CareLink Personal software for patients and CareLink Pro software, to help patients and their health care providers control their diabetes. Customers: The primary medical specialists who use and/or prescribe its Diabetes products are endocrinologists, diabetologists, and internists. Competition: The company’s primary competitors are Johnson & Johnson, DexCom, Inc., Insulet Corporation, and F. Hoffmann-La Roche Ltd. Sales and Marketing The company sells most of its medical devices and therapies through direct sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in markets outside the U.S. Strategy The company’s strategy includes the following: delivering a strong launch cadence of meaningful therapies and procedures; addressing the inequity in health care access globally, primarily in emerging markets; and becoming a leader in value-based health care. Seasonality The number of medical procedures incorporating the company’s products is generally lower during summer months, due to summer vacation schedules in the northern hemisphere, particularly in European countries. Regulations The com

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $77.88 USD +0.41

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.77 USD -0.46
Amgen Inc $171.47 USD -1.27
Bristol-Myers Squibb Co $64.89 USD +0.23
Celgene Corp $132.14 USD -3.28
Eli Lilly & Co $85.09 USD -0.59
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 32.1x
Price/Sales 5.5x
Price/Book 2.1x
Price/Cash Flow 32.1x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.